Immunic, Inc.: valuation
What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.
Cash-flow value
Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.
Your own DCF model
A full discounted-cash-flow model of Immunic, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.
Open the DCF modelAgainst its own history
Immunic, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.
Price to book
5.9×Now above its median of 4.0×, in the top quarter of its range; range 0.5× to 5.9× over 21 months.
as of Oct 28, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 28, 2026.
The statements it starts from
USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.
| Fiscal year | Revenue | Net income | Cash from operations | Capital spending | Free cash flow | Net debt | Source |
|---|---|---|---|---|---|---|---|
| FY2025to Dec 31, 2025 | — | $-97 M | $-86 M | $0 M | $-86 M | — | SEC annual report (10-K, 20-F) |
| FY2024to Dec 31, 2024 | — | $-101 M | $-85 M | $0 M | $-85 M | — | SEC annual report (10-K, 20-F) |
| FY2023to Dec 31, 2023 | — | $-94 M | $-71 M | $0 M | $-71 M | — | SEC annual report (10-K, 20-F) |
| FY2022to Dec 31, 2022 | — | $-120 M | $-65 M | $0 M | $-65 M | — | SEC annual report (10-K, 20-F) |
| FY2021to Dec 31, 2021 | — | $-93 M | $-83 M | $0 M | $-83 M | — | SEC annual report (10-K, 20-F) |
| FY2020to Dec 31, 2020 | — | $-44 M | $-46 M | $0 M | $-46 M | — | SEC annual report (10-K, 20-F) |
Each figure as filed; the full statements with every line and its filing are on the company page. Market value $121 M on Oct 28, 2026.
How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.